

**AMENDMENTS TO THE CLAIMS**

Please add claim 21 as follows:

- 1-6. (Previously Cancelled)
7. (Previously Amended) A method of treating a subject having type C viral hepatitis comprising administering, to the subject, by the peroral route, an oral liquid formulation of human  $\alpha$ -interferon at a daily dosage of between 100 and 500 IU.
8. (Previously Cancelled)
9. (Original) The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from a lymphoblastoid cell culture.
10. (Previously Cancelled)
11. (Previously Amended) The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from lymphocyte cells.
12. (Previously Cancelled)
13. (Original) The method of claim 7 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
14. (Previously Cancelled)
15. (Original) The method of claim 9 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
16. (Previously Cancelled)
17. (Original) The method of claim 11 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.
- 18-20. (Previously Cancelled)

21. (New) A method of treating a subject having type C viral hepatitis comprising administering to the subject a daily dose of a liquid formulation of human  $\alpha$ -interferon, wherein the daily dose is administered by a peroral route, and wherein the daily dose is between 100 and 500 IU.